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Abstract
Background: An effective diagnostic work-up in hospitalized patients with acute ischemic stroke is vital to optimize
secondary stroke prevention. The HEart and BRain interfaces in Acute ischemic Stroke (HEBRAS) study aims to assess
whether an enhanced MRI set-up and a prolonged Holter-ECG monitoring yields a higher rate of pathologic findings
as compared to diagnostic procedures recommended by guidelines (including stroke unit monitoring for at least 24 h,
echocardiography and ultrasound of brain-supplying arteries).
Methods/Design: Prospective observational single-center study in 475 patients with acute ischemic stroke and
without known atrial fibrillation. Patients will receive routine diagnostic care in hospital as wells as brain MRI, cardiac
MRI, MR angiography of the brain-supplying arteries and Holter-monitoring for up to 10 days. Study patients will be
followed up for cardiovascular outcomes at 3 and 12 months after enrolment.
Discussion: By comparing the results of routine diagnostic care to the study-specific MRI/ECG approach, the primary
outcome of HEBRAS is the proportion of stroke patients with pathologic diagnostic findings. Predefined secondary
outcomes are the association of stroke localization, autonomic dysbalance and cardiac dysfunction as well as the effect
of impaired heart-rate-variability on long-term clinical outcome.
The investigator-initiated HEBRAS study will assess whether an enhanced MRI approach and a prolonged ECG
monitoring yield a higher rate of pathological findings than current standard diagnostic care to determine stroke
etiology. These findings might influence current diagnostic recommendations after acute ischemic stroke. Moreover,
HEBRAS will determine the extent and clinical impact of stroke-induced cardiac damage.
Trial registration: Clinicaltrials.gov NCT02142413.
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Background
Variations and delays in the diagnostic procedures dur-
ing hospitalization after acute ischemic stroke are com-
mon [1–3]. At the same time, stroke etiology remains
cryptogenic in about 20–25 % of stroke unit patients [4].
Recent studies have shown that magnetic resonance
imaging (MRI) and MR angiography are able to detect
cardiac [5, 6], aortic [7] as well as carotid sources of em-
bolism with comparable sensitivity as compared to diag-
nostic ultrasound [8]. Moreover, prolonged ECG
monitoring can significantly increase the detection rate
of atrial fibrillation (AF) [9, 10]. The detection of AF im-
plies a four- to fivefold increased risk of stroke [11].
These developments may allow for a more effective diag-
nostic work-up in patients with acute ischemic stroke as
compared to standard diagnostic procedures, namely
ultrasound of the brain-supplying arteries, echocardiog-
raphy and stroke unit monitoring. However, there is no
common standard of stroke unit monitoring [12] and
guidelines [13] do not strictly recommend prolonged
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ECG monitoring [14]. In addition, availability of echo-
cardiography is often limited [1, 15], and a substantial
number of stroke patients are not willing or able to
undergo semi-invasive transesophageal echocardiog-
raphy, while transthoracic echocardiography is not suffi-
cient for assessing aortic plaque and left atrial thrombi.
The prospective observational HEart and BRain inter-
faces in Acute ischemic Stroke (HEBRAS) study therefore
aims to assess the detection rate of pathologic findings
relevant to stroke etiology as obtained by an enhanced
MRI set-up (including brain MRI, cardiac MRI, MR angi-
ography of the brain-supplying arteries) and a prolonged,
non-invasive, commonly available Holter monitoring (of
up to 10 days duration) in comparison to findings ob-
tained by routine diagnostic procedures after acute stroke.
In addition, the underlying pathophysiological mecha-
nisms and the prognostic impact of stroke-induced car-
diac damage are still poorly understood [16, 17]. For that
reason, the investigator-initiated HEBRAS study attempts
to shed more light on the relationship between stroke
localization (e.g., insular involvement), observed cardiac
damage (as indicated by troponin elevation) and the acti-
vation of the autonomic nervous system (as indicated by
impairment of heart rate variability and elevated urinary
norepinephrine levels). Moreover, stroke-induced auto-
nomic dysfunction and observed cardiac damage will be
analyzed with respect to functional outcome, mortality, re-




The Center for Stroke Research Berlin (CSB) is the
sponsor of the investigator initiated HEBRAS study,
which is supported by a grant from the German Federal
Ministry of Education. The study was approved by the
scientific advisory board of the CSB in September 2013,
and by the Ethics Committee of the Charité - Universi-
tätsmedizin Berlin, Germany (EA2/033/14) in March
2014. All study procedures are carried out in accordance
with the principles of Good Clinical Practice and the
Declaration of Helsinki. All study patients have to fulfill
the study entry criteria listed in Table 1 including writ-
ten informed consent.
Study patients will receive routine diagnostic proce-
dures in hospital (defined as stroke unit monitoring (ac-
cording to clinical needs), echocardiography, ultrasound
of the brain-supplying arteries, and 24-hour Holter-ECG
(if indicated according to the treating physician)). More-
over, study patients will undergo an enhanced MRI
work-up (comprising brain as well as cardiac MRI, MR
angiography of the aortic arc and the supra-aortic,
brain-supplying arteries) combined with Holter-ECG of
up to 10 days (including a maximum of 5 days after
hospital discharge). For the primary outcome, the results
of routine diagnostic care will be compared to study-
related diagnostics. Results of the ECG core lab analysis
will be provided to study patients and treating physi-
cians. Study patients will be followed up for cardiovascu-
lar outcomes e.g., recurrent stroke, major vascular
events, death and degree of dependency at 3 and
12 months after enrollment.
Stroke etiology
Etiology will be determined according to TOAST [18]
and ESUS criteria [4]. The following diagnostic findings
will be regarded as pathologic and relevant to stroke eti-
ology: atrial fibrillation of any type, sick sinus syndrome,
bacterial or nonbacterial thrombotic endocarditis, ipsi-
lateral carotid or intracranial stenosis of ≥ 50 % accord-
ing to NASCET [19], left atrial or left ventricular
thrombus, atrial myxoma, acute myocardial infarction
resulting in wall motion abnormalities, akinetic left ven-
tricular segment, dilated cardiomyopathy, systolic dys-
function with reduced left ventricular ejection fraction
(<45 %), aortic plaque of ≥ 4 mm.
Magnetic resonance imaging
In HEBRAS, enhanced diagnostic MRI work-up is de-
fined as brain MRI, cardiac MRI and MR-angiography of
the aortic arc and the brain-supplying arteries. All MR
examinations are performed on a 3 Tesla MR scanner
(TIM TRIO, Siemens, Erlangen, Germany). Cerebral
Table 1 Inclusion and exclusion criteria of the HEBRAS study
Inclusion criteria
• Written informed consent by patient
• Age≥ 18 years.
• Acute ischemic stroke (with matching brain lesion on MR imaging).
• Admission to the stroke unit at the Charité, Campus Benjamin
Franklin
• Enrolment within 144 h after onset of stroke-related symptoms.
Exclusion criteria
• Known AF by past medical history before hospital admission.
• AF according to 12-lead ECG on hospital admission.
• AF according to inpatient ECG recording / stroke unit monitoring
before enrolment.
• Pre-stroke life expectancy less than 1 year.
• Participation in an interventional study.
• Pregnancy and / or breast-feeding.
• Contraindications to undergo MRI (i.e., mechanic heart valve, cardiac
pacemaker)
• History of adverse response to MRI contrast agents
• Clinically severe heart failure (NYHA III-IV) [37]
• Renal insufficiency (creatinine > 1.3 mg/dl (females); creatinine >
1,7 mg/dl (males))
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MRI mainly consists of a T2*-sensitive sequence (TR
620 ms, TE 20 ms, flip angle 20°, FOV 220 mm, slice
thickness 5 mm) to exclude intracerebral hemorrhage, a
diffusion weighted (DWI) sequence (TR 7600 ms, TE
93 ms, FOV 230 mm, slice thickness 2.5 mm) for detec-
tion of ischemic tissue, and a 3D time-of-flight (TOF)
angiographic sequence (TR 22 ms, TE 3.86 ms, flip angle
18°, FOV 200 mm, slice thickness 0.65 mm) for imaging
of intracranial vessels. For cardiac imaging, initially a
dark-blood–prepared HASTE (half-Fourier acquisition
single-shot turbo spin-echo) sequence (TR 750 ms, TE
49 ms, Flip angle 160°, Slice thickness 5 mm) is ac-
quired, followed by 2 chamber as well as 4 chamber view
acquisitions using a cine SSFP sequence (TR 40.56 ms,
TE 1.48 ms, flip angle 50°, slice thickness 5 mm) with
prior scouting for individual frequency adjustment. Post-
contrast imaging is performed after intravenous injection
of 0.1 mmol/kg body weight Gadobutrol (Gadovist®,
Bayer Schering Pharma, Berlin, Germany) with post-
contrast cine imaging parameters held constant. For
angiographic imaging of the aortic arch as well as extra-
cranial cerebral arteries, a three-dimensional TWIST
(Time-resolved angiography With Interleaved Stochastic
Trajectories) sequence was used (TR 2.36 ms, TE
0.99 ms, Flip angle 20°, Slice thickness 1.40 mm). Finally,
myocardial late enhancement is characterised employing
a turbo FLASH (Fast Low Angle SHot) sequence (TR
750.00 ms, TE 1.97 ms, Flip angle 20°, Slice thickness
8 mm).
The following stratification of lesion localization is
planned: left / right anterior cerebral artery, left / right
middle cerebral artery, left / right posterior cerebral ar-
tery, left / right anterior choroideal artery, left / right in-
sular cortex, left / right basal ganglia, left / right
thalamus, left / right cerebellum, left / right brainstem,
left / right medulla oblongata.
To bypass restrictive a priori assumptions on a specific
relationship between stroke lesion and laboratory
changes, an additional voxel-by-voxel analysis of lesion
location and troponin-elevation will be conducted
employing statistical principles developed for functional
brain imaging [20, 21].
Study ECG & core lab analysis
Additional ECG recording will be performed by using
the portable CardioMem®4000 (GETEMED AG, Teltow,
Germany). Study ECG will be started as soon as possible
after enrolment and will be continued for a maximum of
10 days, i.e., two consecutive ECG measurements of five
days. When patients are discharged before the first five
days are completed, ECG recorder will be changed at
discharge, resulting in an overall duration of less than
ten days in Holter-ECG.
Study ECG data will be transmitted to the cardiac core
lab at Department of Cardiology and Pneumology,
Georg-August-University Göttingen, Germany for ana-
lysis. Raters analysing ECG-data will be blinded for clin-
ical data including infarct localization. Core lab analysis
will be provided to the respective study patient and the
patient’s treating physician (if indicated by clinical
assumption).
The following definitions will be used throughout
the study: Atrial fibrillation: Absolute arrhythmia
lasting ≥ 30 s as defined in the current ESC guideline
[22]. Short atrial tachycardia: Atrial tachycardia last-
ing < 30 s and consisting of ≥ 6 conducted premature
activations. Excessive supraventricular ectopic activity:
More than three premature atrial complexes per hour
[23]. Atrial flutter will be reported separately, and the
study specifies to initiate anticoagulation for atrial
flutter in the same way as for AF. The analysis will
include: heart rhythm; PQ intervall [s], minimal
[bpm], maximal [bpm] and mean heart rate (HR)
[bpm], and measures of Heart rate variability (HRV)
such as the standard deviation of beat-to-beat (NN)
intervals (SD-NN), Root Mean Square of Successive
Differences (rMSSD), HRV-Triangular Index (HRV-
TI), low and high frequency (LF and HF, respectively)
band and LF/HF Index [24].
Baseline visit in hospital
Baseline assessment of all study patients will include: a
detailed analysis of patient demographics (also including
time of stroke onset, hospital admission as well as ad-
mittance to the ward), clinical characteristics (including
the National Institutes of Health Scale Score [25] and
the modified Rankin Scale score [26], vital signs, medical
history and concomitant diseases, extend and results of
inpatient ECG recording, laboratory results (all data of
clinical routine assessment plus high-sensitivity (hs)
troponin and NT-proBNP), results of imaging (head CT/
MRI, carotid ultrasound of brain-supplying arteries,
echocardiography) and TOAST classification at hospital
discharge (before evaluation of the additional ECG mon-
itoring), in hospital treatment (i.e., thrombolysis, ventila-
tion etc.) as well as in hospital complications (such as
pneumonia, recurrent stroke or myocardial infarction).
Study follow-up
Follow-up will be done 3 months and one year after the
index stroke by a telephone interview conducted by
trained personal of the Center for Stroke Research
Berlin, Germany. The following data will be assessed:
medication, recurrent ischemic stroke and other major
vascular events, major bleeds, and the mRS score. Add-
itionally, (all-cause) death and date of death will be reg-
istered using information from registration offices.
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Study outcomes
The primary outcome of the HEBRAS study is the rate
of pathologic findings relevant to stroke etiology in pa-
tients with acute ischemic stroke obtained by enhanced
diagnostic MRI work-up combined with prolonged
Holter-monitoring in comparison to findings obtained
by the routine diagnostic work-up in this cohort of pa-
tients. The primary hypothesis is that the detection rate of
pathologic findings can be increased by undergoing en-
hanced diagnostic MRI work-up combined with pro-
longed Holter-monitoring. The primary outcome and all
secondary outcomes are listed in Table 2, and a flowchart
of study specific data acquisition is provided in Table 3.
Statistical analysis
The sample size calculation is based on the aforemen-
tioned primary hypothesis (Table 2), that an enhanced
diagnostic work-up consisting of cerebral and cardiac
MRI (including contrast-enhanced angiography of the
aortic arch and the carotid arteries) combined with a
prolonged ECG-Monitoring (of up to 10 days duration)
leads to a reduction in the number of strokes classified
as cryptogenic from 30 to 25 % when compared to the
routine diagnostic work-up at the Stroke Unit. A sample
size of 396 patients which receive both the enhanced as
well as the routine diagnostic work-up would provide a
power of 79 % to detect a difference in the number of
strokes classified as cryptogenic (from 30 % after routine
diagnostic work-up to 25 % after enhanced diagnostic
work-up, and with assumed 13 % discordant pairs: 9 %
diagnosed as cryptogenic stroke by routine work-up but
not according to enhanced diagnostic work-up, and 4 %
diagnosed as cryptogenic stroke by enhanced work-up
but not according to routine diagnostic work-up). The
hypothesis will be tested using the McNemar-Test (two-
sided, α = 0.05). An interim analysis (with a significance
level of α1 = 0.004) will be performed when 264 patients
(67 %) are enrolled in the study. If p is ≤ α1 at the in-
terim analysis, the study will be terminated. When the
study will be continued, the primary endpoint will be tested
with α2 = 0.046 (two- tailed); the overall significance level
will be 5 %. Taking into account a drop-out rate of about
20 %, 475 patients will have to be enrolled in the study.
Study schedule
The first patient was enrolled in May 2014. We antici-
pate a recruitment period of 18 months, and a recruit-
ment period of additional 12 months is intended to
enroll 475 patients With regard to the planned follow-
up duration, first patient in to last-patient out will be
4.5 years in total.
Discussion
The primary aim of this prospective observational study
is to clarify whether an enhanced diagnostic MRI work-
up combined with prolonged Holter-monitoring leads to
a significant increase in relevant pathologic findings
compared to guideline-recommended routine diagnostic
work-up in patients with acute ischemic stroke without
known atrial fibrillation before enrolment. There is a
vital need to assess potential improvements in stroke
care, because the etiology of about 20–25 % of all ische-
mic strokes remains unknown [4]. The high percentage
of unknown stroke etiology may be explained by low
rates of transesophageal echocardiography [1, 15] and
insufficient duration of ECG monitoring [12]. Compared
to transesophageal echocardiography, cardiac MRI and
MR angiography of the aortic arc are less invasive and
show growing potential for a prominent diagnostic role
in acute ischemic stroke [6]. However, due to lack of
prospective studies, there are no clear cut recommenda-
tions for their clinical use in this context so far. This
study aims to evaluate the efficacy of MRI in detecting
embolic sources of stroke and thereby elucidate its fu-
ture relevance for clinical routine.
Besides feasibility and diagnostic value of enhanced
MRI, HEBRAS will assess the ability of extended system-
atic analysis of ECG-recording to improve AF detection
compared to the current clinical standard, as similarly
done in currently ongoing trials such as the Impact
of Standardized MONitoring for Detection of Atrial
Fibrillation in Ischemic Stroke Study (MonDAFIS)
[NCT02204267] or the Find-AFRANDOMISED trial [27], as
well as previous studies with shorter periods of monitor-
ing [28, 29]. Detection of paroxysmal AF in patients with
acute ischemic stroke represents a major diagnostic
Table 2 Primary outcome and secondary outcomes of the
HEBRAS study
Primary outcome
• Detection rate of pathologic findings relevant to stroke etiology in
patients with acute ischemic stroke obtained by enhanced diagnostic
MRI work-up combined with prolonged Holter-monitoring in
comparison to findings obtained by routine diagnostic work-up.
Secondary outcomes
• To assess the benefit of prolonged continuous ECG-monitoring in
AIS patients to detect paroxysmal AF.
• To determine the proportion of patients with first detected
paroxysmal AF by prolonged Holter-monitoring (for up to 5 days)
after hospital discharge.
• To identify the impact of stroke localization on autonomic changes
(as indicated by elevated urinary norepinephrine levels and
measures of HRV) or cardiac dysfunction (as indicated by troponin T
serum levels).
• To identify the impact of impaired HRV on recurrent vascular events
and clinical outcome after AIS at 3 or 12 months after the index
stroke, respectively.
• To assess the predictive value of imaging and biomarkers for
AF-detection in patients with acute ischemic stroke.
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challenge nowadays, and AF remains undetected in a
relevant proportion of stroke patients [9, 10]. A faster
assessment and better understanding of stroke etiology
may improve secondary stroke prevention measures and
thereby help to reduce the rate of stroke recurrence.
Another unique feature of the investigator-initiated
HEBRAS study is the systematic assessment of stroke-
induced autonomic dysfunction and cardiac damage by
using a laboratory data. It has long been recognized that
acute cerebrovascular events may coincide with or trig-
ger cardiac dysfunction and elevation of cardiac bio-
markers such as troponin. Several studies reported on
elevation of cTn in patients with acute ischemic stroke
[30–32]. However, although cTn is highly specific for
myocardial injury, it does not reveal the underlying
mechanism of injury. Elevations in cTn do not necessar-
ily signify coronary myocardial ischemia. There are po-
tential other causes of cTn elevations without underlying
acute or chronic CAD [33]. One possible mechanism of
acute cardiac injury in ischemic stroke, which pertains
exclusively to patients with acute disease of the central
nervous system, is neurogenic myocardial damage.
Neurogenic myocardial damage may be caused by
impairments within the central autonomic network. A
crucial player of the central autonomic network would
be the insula. Within a previous work, we have shown a
positive association between stroke affecting the insula
and troponin elevation [31]. Therefore, HEBRAS will
elucidate the relationship between stroke location and
troponin elevation with measures of voxel based lesion
mapping.
In addition, natriuretic peptides (e.g., BNP) have been
shown to be independently associated with atrial fibrilla-
tion in stroke cohorts [34–36], but have not been evalu-
ated in large prospective trials thus far.
Conclusion
In summary, the HEBRAS study aims to clarify whether
recent technical advantages can improve etiologic work
up after acute ischemic stroke. This study has the poten-
tial to set essential modifications of current diagnostic
standards after acute ischemic stroke, aiming at improv-
ing secondary stroke prevention. Moreover, the HEBRAS
study will hopefully elucidate mechanisms of stroke-
induced autonomic dysfunction and cardiac damage.
Table 3 Study flowchart of the HEBRAS study
In-hospital stay Follow-up
Admission Day 1 Day ≥2 Discharge 3 months 12 months
Baseline data* X
Past medical history X X X
Heart rate at rest (routine) X X Daily X
Heart rhythm (routine) X X Daily X
12-lead ECG X
24-hour Holter (X)
Additional ECG monitoringa ongoing ongoingc
Respiratory rate X X Daily
Clinical signs of infection X X X
Leukocytes [per mm3] X
Creatinine [mg/dl] X
Potassium [mmol/l] X
Serum hs troponin I [ng/l] X X
NT-proBNP [ng/l] X





Modified Rankin scale score X X X X
Recurrent stroke, myocardial infarction or death of any cause X X X
asee Methods section for more details
bincluding the aortic arc and brain supplying arteries
cextended for up to 5 days after hospital discharge/ transfer to a rehabilitation clinic
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AF: Atrial fibrillation; bpm: Beats per minute; ECG: Electrocardiogramm;
ESUS: Embolic Stroke of undetermined Source; FOV: Field of view;
HEBRAS: HEart and BRain interfaces in Acute ischemic Stroke; HRV: Heart rate
variability; HRV-TI: HRV-Triangular Index; LF: Low frequency; HF: High
frequency; MRI: Magnetic resonance imaging; NASCET: North American
symptomatic carotid endarterectomy trial; NYHA: New York heart association;
s: Seconds; rMSSD: Root mean square of successive differences; SD-
NN: Standard deviation of beat-to-beat intervals; TE: Echo time;
TEE: Transesophageal echocardiography; TOAST: Trial of ORG 10172 in acute
stroke treatment; TR: Repetition time; TTE: Transthoracal echocardiography.
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